Semax Stimulates BDNF Expression in the Rat Brain and Exerts Neuroprotective Effects
Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynin VA, Zarindast MR, Grivennikov IA
Journal of Neurochemistry · Vol. 97(Suppl 1) · pp. 82–86 · 2006
Demonstrates that Semax significantly upregulates BDNF (brain-derived neurotrophic factor) and NGF expression in multiple brain regions. The peptide shows neuroprotective effects in models of ischemia and oxidative stress. These findings provide the mechanistic basis for Semax's cognitive-enhancing and neuroprotective properties.
Key Findings
Semax increases BDNF mRNA expression by 1.4–2.0 fold in hippocampus and cortex
Upregulates NGF expression, supporting neuronal survival and plasticity
Demonstrates neuroprotective effects in cerebral ischemia models
Enhances memory consolidation in behavioral tests
Approved in Russia for cognitive disorders and stroke treatment
Methodology
In vivo rat studies using RT-PCR for BDNF/NGF quantification, combined with behavioral testing and ischemia models. Includes dose-response characterization.
Limitations
Animal model data; limited controlled human trial data outside Russia. Intranasal bioavailability in humans not fully characterized.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment